<!DOCTYPE html>
<!-- Generated by pkgdown: do not edit by hand --><html lang="en">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
<meta charset="utf-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<title>Payoffs • epicR</title>
<script src="../deps/jquery-3.6.0/jquery-3.6.0.min.js"></script><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<link href="../deps/bootstrap-5.3.1/bootstrap.min.css" rel="stylesheet">
<script src="../deps/bootstrap-5.3.1/bootstrap.bundle.min.js"></script><link href="../deps/font-awesome-6.5.2/css/all.min.css" rel="stylesheet">
<link href="../deps/font-awesome-6.5.2/css/v4-shims.min.css" rel="stylesheet">
<script src="../deps/headroom-0.11.0/headroom.min.js"></script><script src="../deps/headroom-0.11.0/jQuery.headroom.min.js"></script><script src="../deps/bootstrap-toc-1.0.1/bootstrap-toc.min.js"></script><script src="../deps/clipboard.js-2.0.11/clipboard.min.js"></script><script src="../deps/search-1.0.0/autocomplete.jquery.min.js"></script><script src="../deps/search-1.0.0/fuse.min.js"></script><script src="../deps/search-1.0.0/mark.min.js"></script><!-- pkgdown --><script src="../pkgdown.js"></script><meta property="og:title" content="Payoffs">
<style>
/* Event table styles */
.event-table table {
    width: 100%;
    border-collapse: collapse;
    margin: 20px 0;
    font-size: 1em;
    font-family: Arial, sans-serif;
    text-align: left;
    border: none;
}
.event-table table th {
    background-color: #f3f4f5;
    font-weight: bold;
    border-bottom: 3px solid #333;
    padding: 10px;
}
.event-table table td {
    padding: 8px;
}
.event-table table tr:nth-child(even) {
    background-color: #f3f4f5;
}
.event-table table tr:nth-child(odd) {
    background-color: #ffffff;
}

/* Dropdown table styles */
.custom-table-container-dropdown table {
    width: 100%;
    table-layout: fixed;
    border-collapse: collapse;
    margin: 20px 0;
    font-size: 1em;
    font-family: Arial, sans-serif;
    text-align: left;
    border: 1px solid #ddd;
}
.custom-table-container-dropdown table th {
    background-color: #f3f4f5;
    font-weight: bold;
    border-bottom: 3px solid #333;
    padding: 10px;
    text-align: left;
}
.custom-table-container-dropdown table td {
    padding: 8px;
}
.btn-primary {
    color: #fff;
    background-color: #007bff;
    border: none;
    padding: 5px 10px;
    font-size: 0.9em;
    cursor: pointer;
    border-radius: 3px;
}
.btn-primary:hover {
    background-color: #0056b3;
}
.custom-collapse {
    margin-top: 10px;
    padding: 10px;
    border: 1px solid #ddd;
    background-color: #f9f9f9;
    display: none;
}
.custom-collapse.show {
    display: block;
}

/* General table styles */
.custom-table-container table {
    width: 100%;
    border-collapse: collapse;
    margin: 20px 0;
    font-size: 1em;
    font-family: Arial, sans-serif;
    text-align: left;
    border: 1px solid #ddd;
}
.custom-table-container table th {
    background-color: #f3f4f5;
    font-weight: bold;
    border-bottom: 3px solid #333;
    padding: 10px;
    text-align: left;
}
.custom-table-container table td {
    padding: 8px;
    border-bottom: 1px solid #ddd;
}
.custom-table-container table tr:nth-child(even) {
    background-color: #f9f9f9;
}
.custom-table-container table tr:nth-child(odd) {
    background-color: #ffffff;
}
.custom-table-container table tr:hover {
    background-color: #b780ff;
}
</style>
<script>
document.addEventListener('DOMContentLoaded', function() {
  document.querySelectorAll('.btn-primary').forEach(function(button) {
    button.addEventListener('click', function() {
      var target = document.querySelector(button.getAttribute('data-target'));
      if (target) {
        target.classList.toggle('show');
      }
    });
  });
});
</script>
</head>
<body>
    <a href="#main" class="visually-hidden-focusable">Skip to contents</a>


    <nav class="navbar navbar-expand-lg fixed-top bg-light" data-bs-theme="light" aria-label="Site navigation"><div class="container">

    <a class="navbar-brand me-2" href="../index.html">epicR</a>

    <small class="nav-text text-muted me-auto" data-bs-toggle="tooltip" data-bs-placement="bottom" title="">0.9.0</small>


    <button class="navbar-toggler" type="button" data-bs-toggle="collapse" data-bs-target="#navbar" aria-controls="navbar" aria-expanded="false" aria-label="Toggle navigation">
      <span class="navbar-toggler-icon"></span>
    </button>

    <div id="navbar" class="collapse navbar-collapse ms-3">
      <ul class="navbar-nav me-auto">
<li class="nav-item"><a class="nav-link" href="../reference/index.html">Reference</a></li>
<li class="active nav-item dropdown">
  <button class="nav-link dropdown-toggle" type="button" id="dropdown-articles" data-bs-toggle="dropdown" aria-expanded="false" aria-haspopup="true">Articles</button>
  <ul class="dropdown-menu" aria-labelledby="dropdown-articles">
<li><a class="dropdown-item" href="../articles/AddingNewCountry.html">Adding a New Country to epicR</a></li>
    <li><a class="dropdown-item" href="../articles/BackgroundEPIC.html">EPIC Background</a></li>
    <li><a class="dropdown-item" href="../articles/Calibrate_COPD_Exacerbations.html">Calibrate COPD Exacerbations</a></li>
    <li><a class="dropdown-item" href="../articles/Calibrate_COPD_Prevalence.html">Calibrate COPD Prevalence</a></li>
    <li><a class="dropdown-item" href="../articles/Calibrate_Demographics.html">Calibrate Demographics</a></li>
    <li><a class="dropdown-item" href="../articles/Calibrate_Smoking.html">Calibrate Smoking Status</a></li>
    <li><a class="dropdown-item" href="../articles/GettingStarted.html">Getting Started with EPIC</a></li>
    <li><a class="dropdown-item" href="../articles/Payoffs.html">Payoffs</a></li>
    <li><a class="dropdown-item" href="../articles/RecalibratingEPIC.html">RecalibratingEPIC</a></li>
    <li><a class="dropdown-item" href="../articles/Reproducing_bgd.html">Reproducing Background Mortality</a></li>
    <li><a class="dropdown-item" href="../articles/UsingEPICinR.html">Using EPIC in R</a></li>
  </ul>
</li>
      </ul>
<ul class="navbar-nav">
<li class="nav-item"><form class="form-inline" role="search">
 <input class="form-control" type="search" name="search-input" id="search-input" autocomplete="off" aria-label="Search site" placeholder="Search for" data-search-index="../search.json">
</form></li>
      </ul>
</div>


  </div>
</nav><div class="container template-article">




<div class="row">
  <main id="main" class="col-md-9"><div class="page-header">

      <h1>Payoffs</h1>
            
      

      <div class="d-none name"><code>Payoffs.Rmd</code></div>
    </div>

    
    
<div class="section level2">
<h2 id="overview">Overview<a class="anchor" aria-label="anchor" href="#overview"></a>
</h2>
<p>This document outlines the steps taken to determine input values for
the payoff module.</p>
<div class="section level3">
<h3 id="step-1-estimating-annual-copd-medication-costs">Step 1: Estimating annual COPD medication costs<a class="anchor" aria-label="anchor" href="#step-1-estimating-annual-copd-medication-costs"></a>
</h3>
<p>Annual COPD medication costs were estimated using two components:</p>
<ol style="list-style-type: decimal">
<li>
<strong>Inhaler unit cost by drug class</strong>
<ul>
<li>Prices were obtained from published literature (DOI:
10.1513/AnnalsATS.202008-1082RL). Prices of SABA and LAMA were digitized
from Figure 2A as these prices were not reported in the text.</li>
<li>It was assumed that one inhaler is used per month per drug class,
resulting in 12 inhalers annually.<br>
</li>
<li>Annual cost per drug class (2018 Costs USD) was calculated as:<br><code>Annual Cost = Inhaler Unit Price × 12</code>
</li>
</ul>
</li>
<li>
<strong>Real-world dispensing frequency based on proportion of days
covered (PDC)</strong>
<ul>
<li>PDC estimates were used to determine adherence to inhaler
therapies</li>
<li>Sources for PDC data include:
<ul>
<li>
<strong>Mannino et al. 2022</strong> (DOI:
10.1016/j.rmed.2022.106807)</li>
<li>
<strong>Slade et al. 2021</strong> (DOI:
10.1186/s12890-021-01612-5)</li>
<li>
<strong>Bengtson et al. 2018</strong> (DOI:
10.1177/1753466618772750)</li>
</ul>
</li>
</ul>
</li>
</ol>
<div class="section level5">
<h5 id="dispense-frequency-per-year-adjusted-via-pdc">Dispense frequency per year (adjusted via PDC)<a class="anchor" aria-label="anchor" href="#dispense-frequency-per-year-adjusted-via-pdc"></a>
</h5>
<p><strong>Mannino et al. 2022:</strong><br>
- <strong>ICS + LAMA + LABA</strong>: PDC = 0.66</p>
<p><strong>Slade et al. 2021:</strong><br>
- <strong>LAMA + LABA</strong>: PDC = 0.44<br>
- <strong>LAMA</strong>: PDC = 0.37</p>
<p><strong>Bengtson et al. 2018</strong> - <strong>SABA</strong>: The
study reported an average of 1 fill per month</p>
<p><strong>Adherence:</strong> Adherence was determined to be an average
of the PDC reported between the studies that assessed non-SABA inhalers=
0.49.</p>
<table class="table">
<caption>Estimated Annual COPD Inhaler Costs by Drug Class</caption>
<colgroup>
<col width="22%">
<col width="23%">
<col width="18%">
<col width="35%">
</colgroup>
<thead><tr class="header">
<th align="left">Drug Class</th>
<th align="right">Monthly Cost (USD)</th>
<th align="right">Dispenses/Year</th>
<th align="right">Estimated Annual Cost (USD)</th>
</tr></thead>
<tbody>
<tr class="odd">
<td align="left">ICS + LAMA + LABA</td>
<td align="right">296.11</td>
<td align="right">12</td>
<td align="right">3,553.32</td>
</tr>
<tr class="even">
<td align="left">LAMA</td>
<td align="right">208.10</td>
<td align="right">12</td>
<td align="right">2,497.20</td>
</tr>
<tr class="odd">
<td align="left">LAMA+LABA</td>
<td align="right">218.05</td>
<td align="right">12</td>
<td align="right">2,616.60</td>
</tr>
<tr class="even">
<td align="left">SABA</td>
<td align="right">32.20</td>
<td align="right">12</td>
<td align="right">386.40</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="section level3">
<h3 id="step-2-estimating-copd-related-background-costs-by-gold-stage">Step 2: Estimating COPD-related background costs by GOLD stage<a class="anchor" aria-label="anchor" href="#step-2-estimating-copd-related-background-costs-by-gold-stage"></a>
</h3>
<p>COPD-related background costs were estimated using data from Wallace
et al 2019 (DOI: 10.18553/jmcp.2019.25.2.205) Table 3, specifically the
row labeled “COPD-related costs, all patients”. Background costs were
calculated by subtracting the costs of <strong>Inpatient Care</strong>,
<strong>Emergency Room (ER) Visits</strong>, and
<strong>Pharmacy</strong> from the <strong>Total COPD-related Medical
Costs</strong> (2016 Costs USD) as these costs are determined
separately.</p>
<table class="table">
<caption>COPD-related Background Costs by GOLD Stage</caption>
<colgroup>
<col width="11%">
<col width="34%">
<col width="10%">
<col width="10%">
<col width="9%">
<col width="23%">
</colgroup>
<thead><tr class="header">
<th align="left">GOLD Stage</th>
<th align="right">Total COPD-related Medical Costs</th>
<th align="right">Inpatient</th>
<th align="right">ER Visits</th>
<th align="right">Pharmacy</th>
<th align="right">Background Cost (USD)</th>
</tr></thead>
<tbody>
<tr class="odd">
<td align="left">GOLD I</td>
<td align="right">5,945</td>
<td align="right">3,853</td>
<td align="right">186</td>
<td align="right">592</td>
<td align="right">1,314</td>
</tr>
<tr class="even">
<td align="left">GOLD II</td>
<td align="right">6,978</td>
<td align="right">4,449</td>
<td align="right">144</td>
<td align="right">1,101</td>
<td align="right">1,284</td>
</tr>
<tr class="odd">
<td align="left">GOLD III</td>
<td align="right">10,751</td>
<td align="right">6,277</td>
<td align="right">193</td>
<td align="right">2,000</td>
<td align="right">2,281</td>
</tr>
<tr class="even">
<td align="left">GOLD IV</td>
<td align="right">18,070</td>
<td align="right">12,139</td>
<td align="right">534</td>
<td align="right">2,479</td>
<td align="right">2,918</td>
</tr>
</tbody>
</table>
</div>
<div class="section level3">
<h3 id="step-3-estimating-exacerbation-costs-by-severity">Step 3: Estimating exacerbation costs by severity<a class="anchor" aria-label="anchor" href="#step-3-estimating-exacerbation-costs-by-severity"></a>
</h3>
<p>The exacerbation module assigns per-event direct medical costs based
on severity: <strong>Mild</strong>, <strong>Moderate</strong>,
<strong>Severe</strong>, and <strong>Very Severe</strong>. These cost
estimates were derived from U.S.-based healthcare utilization
studies.</p>
<ul>
<li>
<strong>Mild Exacerbation</strong>: Defined as an increase in
bronchodilator use that does not result in a healthcare encounter. It is
assumed that half of the number of available doses in a SABA inhaler is
used per event. Cost of SABA inhaler is obtained from the published
literature (DOI: 10.1513/AnnalsATS.202008-1082RL).</li>
<li>
<strong>Moderate Exacerbation</strong>: Involves a visit to a
healthcare facility (e.g., physician office or emergency department)
without resulting in hospital admission.</li>
<li>
<strong>Severe Exacerbation</strong>: Defined as an inpatient
hospital admission</li>
<li>
<strong>Very Severe Exacerbation</strong>: Defined as ICU
admission</li>
</ul>
<p>The following references were used:</p>
<ul>
<li>
<strong>Dalal et al. 2011</strong> (DOI: 10.1016/j.rmed.2010.09.003)
— 2008 Costs USD<br>
</li>
<li>
<strong>Bogart et al. 2020</strong> (DOI: 10.37765/ajmc.2020.43157)
— 2017 Costs USD</li>
</ul>
<table style="width:100%;" class="table">
<caption>Per-Event COPD Exacerbation Costs by Severity</caption>
<colgroup>
<col width="26%">
<col width="38%">
<col width="13%">
<col width="22%">
</colgroup>
<thead><tr class="header">
<th align="left">Exacerbation Severity</th>
<th align="left">Definition</th>
<th align="right">Cost (USD)</th>
<th align="left">Source</th>
</tr></thead>
<tbody>
<tr class="odd">
<td align="left">Mild</td>
<td align="left">Increased SABA medication usage</td>
<td align="right">16.1</td>
<td align="left">Assumption</td>
</tr>
<tr class="even">
<td align="left">Moderate</td>
<td align="left">No hospitalization</td>
<td align="right">2,107.0</td>
<td align="left">Bogart et al. 2020</td>
</tr>
<tr class="odd">
<td align="left">Severe</td>
<td align="left">Inpatient hospitalization</td>
<td align="right">22,729.0</td>
<td align="left">Bogart et al. 2020</td>
</tr>
<tr class="even">
<td align="left">Very Severe</td>
<td align="left">ICU + intubation</td>
<td align="right">44,909.0</td>
<td align="left">Dalal et al. 2011</td>
</tr>
</tbody>
</table>
</div>
<div class="section level3">
<h3 id="step-4-estimating-costs-for-smoking-cessation">Step 4: Estimating costs for smoking cessation<a class="anchor" aria-label="anchor" href="#step-4-estimating-costs-for-smoking-cessation"></a>
</h3>
</div>
<div class="section level3">
<h3 id="estimating-the-cost-of-smoking-cessation-therapy">Estimating the Cost of Smoking Cessation Therapy<a class="anchor" aria-label="anchor" href="#estimating-the-cost-of-smoking-cessation-therapy"></a>
</h3>
<p>To estimate the cost of smoking cessation therapy, the distribution
of commonly used pharmacologic and behavioral therapies was obtained
from the MMWR study (DOI: 10.15585/mmwr.mm7329a1). The reported usage
among individuals attempting to quit included:</p>
<ul>
<li>
<strong>Nicotine patch</strong>: 19.6%<br>
</li>
<li>
<strong>Nicotine gum/lozenge</strong>: 18.4%<br>
</li>
<li>
<strong>Nicotine spray/inhaler</strong>: 1.0%<br>
</li>
<li>
<strong>Varenicline</strong>: 9.6%<br>
</li>
<li>
<strong>Bupropion</strong>: 6.4%<br>
</li>
<li>
<strong>Behavioral counseling</strong>: 7.3%</li>
</ul>
<div class="section level4">
<h4 id="reweighted-to-assume-100-uptake">Reweighted to Assume 100% Uptake<a class="anchor" aria-label="anchor" href="#reweighted-to-assume-100-uptake"></a>
</h4>
<p>To standardize the distribution across therapies, reweighting was
performed using the total of all therapies (62.3%):</p>
<ul>
<li>
<strong>Nicotine patch</strong>: (19.6 / 62.3) × 100 ≈
<strong>31.5%</strong><br>
</li>
<li>
<strong>Nicotine gum/lozenge</strong>: (18.4 / 62.3) × 100 ≈
<strong>29.5%</strong><br>
</li>
<li>
<strong>Nicotine spray/inhaler</strong>: (1.0 / 62.3) × 100 ≈
<strong>1.6%</strong><br>
</li>
<li>
<strong>Varenicline</strong>: (9.6 / 62.3) × 100 ≈
<strong>15.4%</strong><br>
</li>
<li>
<strong>Bupropion</strong>: (6.4 / 62.3) × 100 ≈
<strong>10.3%</strong><br>
</li>
<li>
<strong>Behavioral counseling</strong>: (7.3 / 62.3) × 100 ≈
<strong>11.7%</strong>
</li>
</ul>
</div>
<div class="section level4">
<h4 id="estimated-3-month-cost-of-smoking-cessation-therapy">Estimated 3-Month Cost of Smoking Cessation Therapy<a class="anchor" aria-label="anchor" href="#estimated-3-month-cost-of-smoking-cessation-therapy"></a>
</h4>
<p>Cost estimates were based on 2025 GoodRx prices for a 3-month course
of pharmacotherapy.<br>
For behavioral counseling, Medicare reimburses up to 8 sessions per
year, which was assumed to be the number of sessions used.<br>
The per-session cost was based on <strong>2015 CPT codes</strong>:</p>
<ul>
<li>
<strong>99406</strong>: $14.37 for sessions &lt;10 minutes<br>
</li>
<li>
<strong>99407</strong>: $27.67 for sessions &gt;10 minutes</li>
</ul>
<p>A midpoint value of <strong>$21.02</strong> per session was applied,
totaling <strong>$168.16</strong> for 8 sessions.</p>
<p>Using the reweighted proportions, the weighted average cost for 3
months of smoking cessation pharmacotherapy was calculated as:</p>
<p><strong>Average cost</strong>: $125.65</p>
<table class="table">
<caption>Smoking Cessation Therapy Use and Cost Estimates (3-Month
Duration)</caption>
<thead><tr class="header">
<th align="left">Therapy</th>
<th align="left">Reweighted Proportion (%)</th>
<th align="right">Cost (USD)</th>
</tr></thead>
<tbody>
<tr class="odd">
<td align="left">Nicotine Patch</td>
<td align="left">31.5</td>
<td align="right">71.00</td>
</tr>
<tr class="even">
<td align="left">Nicotine Gum/Lozenge</td>
<td align="left">29.5</td>
<td align="right">35.00</td>
</tr>
<tr class="odd">
<td align="left">Nicotine Spray/Inhaler</td>
<td align="left">1.6</td>
<td align="right">550.00</td>
</tr>
<tr class="even">
<td align="left">Varenicline</td>
<td align="left">15.4</td>
<td align="right">402.00</td>
</tr>
<tr class="odd">
<td align="left">Bupropion</td>
<td align="left">10.3</td>
<td align="right">25.00</td>
</tr>
<tr class="even">
<td align="left">Behavioral Counseling</td>
<td align="left">11.7</td>
<td align="right">168.16</td>
</tr>
<tr class="odd">
<td align="left">Average (weighted)</td>
<td align="left">–</td>
<td align="right">125.65</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="section level3">
<h3 id="step-5-estimating-costs-for-gp-visits-and-diagnostic-spirometry">Step 5: Estimating costs for GP visits and diagnostic
spirometry<a class="anchor" aria-label="anchor" href="#step-5-estimating-costs-for-gp-visits-and-diagnostic-spirometry"></a>
</h3>
<p><strong>GP visits</strong>.<br>
CPT code 99214 is a standard outpatient GP visit, the midpoint between
facility and non facility visit reimbursement amounts was used which
equates $94.15 (2015 Costs USD)</p>
<p><strong>Spirometry</strong>. CPT code 94060 was used which equates to
$61.81 (2015 Costs USD)</p>
</div>
</div>
  </main><aside class="col-md-3"><nav id="toc" aria-label="Table of contents"><h2>On this page</h2>
    </nav></aside>
</div>



    <footer><div class="pkgdown-footer-left">
  <p>Developed by Mohsen Sadatsafavi, Amin Adibi, Kate Johnson.</p>
</div>

<div class="pkgdown-footer-right">
  <p>Site built with <a href="https://pkgdown.r-lib.org/" class="external-link">pkgdown</a> 2.2.0.</p>
</div>

    </footer>
</div>





  </body>
</html>
